- Home
- GFUZW vs SLN Comparison
GFUZW vs SLN Comparison
Compare GFUZW & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFUZW | SLN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.2M | 300.9M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | GFUZW | SLN |
|---|---|---|
| Price | $1.87 | $10.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | N/A | ★ 622.1K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $4.19 |
| 52 Week High | $1.82 | $11.19 |
Technical Indicators
Market Signals| Indicator | GFUZW | SLN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 65.20 |
| Support Level | N/A | $5.87 |
| Resistance Level | N/A | $11.06 |
| Average True Range (ATR) | 0.00 | 0.80 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 85.53 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.